Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Ciwon sankarar lymphoblastic mai tsanani (T-ALL)-06

Majiyyaci: Xiaohong

JinsiNamiji

Shekaru: shekara 2

Ƙasa: Sinanci

Ganewar GanewaCiwon sankarar lymphoblastic mai tsanani (T-ALL)

    Majinyacin yara ɗan shekara 2 da ke fama da cutar T-ALL ya sami sauƙi bayan an yi masa maganin CAR-T bayan an shafe sama da zagaye goma ana amfani da maganin chemotherapy mai ƙarfi.


    An gano Xiaohong mai shekaru biyu daga Zhejiang yana da cutar sankarar bargo a bazarar da ta gabata. Bayan fiye da shekara guda na magani, sinadarin jini ya gano sake dawowa, wanda hakan ya sa iyalin suka nemi maganin rigakafi na CAR-T a BIOOCUS Medical Group.


    A ranar 9 ga Agusta, 2020, an kwantar da Xiaohong a wani asibiti na yara na yankin saboda "zazzabi na kwana uku." Binciken MICM na bargon ƙashi ya gano cutar sankarar lymphoblastic mai tsanani (T-ALL). Bayan wani gwaji na chemotherapy, yanayin bargon ƙashi ya nuna cikakkiyar sassauci, kuma kwararar cytometry ta gano babu ƙwayoyin halitta marasa lafiya. Maganin chemotherapy mai ƙarfi na baya-bayan nan sama da darussa 11 ya ci gaba da warkar da bargon ƙashi gaba ɗaya.


    A ranar 3 ga Satumba, 2021, an yi wa wani huda a ƙashi bayan an yi masa tiyata ya nuna cewa ya warke gaba ɗaya a fannin yanayin jikinsa, amma binciken ƙwayoyin halitta na kwarara ya nuna kashi 1.85% na ƙwayoyin da ba su kai ba. Don neman ƙarin magani, an shigar da Xiaohong a cibiyarmu ta CGT a ranar 24 ga Satumba. Bayan an yi masa tiyata, yanayin ƙashi har yanzu yana cikin cikakkiyar sauƙi, amma gwajin immunophenotyping ya nuna cewa akwai ƙwayoyin T masu kama da ba su kai ba 0.10%.


    Ganin ƙaramar shekarun Xiaohong da kuma juriyar cutar duk da fiye da zagaye goma na maganin chemotherapy mai tsanani, ƙungiyar likitoci a sashe na biyu na sashen kula da cututtukan jini ta yanke shawarar cewa Xiaohong zai iya shiga gwajin asibiti na CD7 CAR-T.


    A ranar 30 ga Satumba, 2021, an tattara ƙwayoyin jini na gefe don haɓaka ƙwayoyin CAR-T. A ranar 10 ga Oktoba, Xiaohong ya karɓi maganin chemotherapy na tsarin FC. A ranar 13 ga Oktoba, an huda ƙashi da kashi ya nuna ƙasa da kashi 5% na fashewar a cikin yanayin halittar jiki, kuma kwararar cytometry ta nuna kashi 0.37% na ƙwayoyin T marasa ƙarfi. A ranar 15 ga Oktoba, an sake haɗa ƙwayoyin CD7 CAR-T.


    A ranar 3 ga Janairu (kwanaki 20 bayan sake haɗawa), huda ƙashi ya nuna cikakkiyar sassauci a fannin yanayin jiki, ba tare da gano ƙwayoyin halitta marasa ƙarfi da suka balaga ta hanyar cytometry na kwarara ba. Tun daga lokacin yanayin Xiaohong ya daidaita, kuma an mayar da shi sashen dashen don shirya yin dashen ƙwayoyin halitta na allogeneic hematopoietic.


    Xiaohong bai kai shekara ɗaya ba lokacin da ya yi rashin lafiya kuma ya sha fama da shan magani na tsawon shekara guda. Nasarar da aka samu wajen dashen bayan maganin CD7 CAR-T ya samar da makami mai ƙarfi don kawar da cutar gaba ɗaya.

    4mm3

    Tun daga watan Yulin 2015, cibiyarmu ta CGT ta fara gwajin asibiti na maganin ƙwayoyin CAR AT a cikin cututtukan jini. A matsayinta na ɗaya daga cikin rukunin farko da suka fara maganin ƙwayoyin CAR-T a China, marasa lafiya 1342 sun shiga gwajin zuwa yanzu, kuma bayanan asibiti sun nuna inganci da aminci mai kyau. CD7 glycoprotein 40 kDa ne wanda ke cikin dangin immunoglobulin, kuma CD7 na yau da kullun galibi ana bayyana shi akan ƙwayoyin T da ƙwayoyin NK da kuma a farkon matakan bambance-bambancen ƙwayoyin T, B da myeloid, kuma yana iya aiki a matsayin mai karɓar costimulatory don hulɗa tsakanin ƙwayoyin T da B yayin haɓakar lymphocytes. CD7 alama ce mai ƙarfi a saman ƙwayoyin T kuma a halin yanzu ana kimanta ta a matsayin sabuwar manufa tare da maganin ƙwayoyin CAR T don cututtukan jini. Kwanan nan, a cikin sashe na biyu na Sashen Hematology na Asibitin Ludaopei, marasa lafiya 4 tare da yanayi masu rikitarwa sun sami sakamako bayyananne bayan maganin CD7 CAR-T.

    bayanin2

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write